Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP04 vs Avastin plus paclitaxel/carboplatin in advanced non-squamous NSCLC
CTR20192708Phase 3Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SIBP-04 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Jan 2020; status: completed.
02
Drugs
SIBP-04
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20192708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192708.